Maxim_Group reiterates Buy on AB_Science
Analysis based on 6 articles · First reported May 25, 2026 · Last updated May 25, 2026
The reiteration of a Buy recommendation by Maxim Group>>> for AB Science>>>'s stock, coupled with a €4.00 target price, is likely to positively impact AB Science>>>'s stock performance. The securing of a clinical trial insurance policy for masitinib's Phase 3 ALS study de-risks the investment, potentially attracting new investors and facilitating financing for the program.
Maxim Group>>>, an independent US-based investment bank, has reiterated its Buy recommendation on AB Science>>>'s stock with a target price of €4.00 per share. This recommendation follows AB Science>>>'s release of its FYE2025 results and the securing of a €25M (up to €39M) clinical trial insurance policy offer in April 2026 to protect against Phase 3 failure and costs for masitinib in ALS (ALS). AB Science>>> has strategically refocused its efforts on developing masitinib for ALS and AB8939 for Acute myeloid leukemia (AML), pausing other clinical trials to reduce operating costs and expedite high-value programs. The clinical trial insurance policy is expected to de-risk AB Science>>> for investors, making financing for the Phase 3 ALS study more attractive. Masitinib has shown promising results in treating ALS patients, demonstrating functional and survival benefits.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard